Emesis
16
0
0
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
18.8%
3 terminated out of 16 trials
75.0%
-11.5% vs benchmark
25%
4 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (16)
Promoting Safe Medication Use in Pregnancy in the Era of Real-World Data - The SafeStart Study
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
Evaluation of Meclizine Orodispersible Tablet Pharmacokinetic in Human Volunteers
Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia
DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
Different Feeding Methods After Pyloromyotomy
High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy